Ambramycin

Ambramycin is a tetracycline antibiotic historically indicated for infections caused by susceptible strains of specific organisms, such as:

• Streptococcus pneumoniae
• Mycoplasma pneumoniae
• Chlamydia trachomatis

Structurally related to other tetracyclines, it has largely been superseded by agents with improved pharmacokinetics and safety profiles, including:

• Doxycycline
• Minocycline
• Eravacycline
• Sarecycline

Ambramycin is not currently listed in the European Medicines Agency (EMA) or U.S. Food and Drug Administration (FDA) databases, suggesting it is no longer authorized or actively marketed in the EU or USA. No recent clinical trials involving Ambramycin are registered on ClinicalTrials.gov, and no safety updates or SmPCs are available via the Electronic Medicines Compendium or Drugs.com. This supports its classification as a legacy antibiotic.

By Megan Lee

Developed by EPG Health for Medthority, independently of any sponsor.